Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (August 2022)
25 slides from Inoviq's investor presentation, Aug 9, 2022
Slide 1: Investor Presentation
Investor Presentation ASX: IIQ | 9 August 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on Actual results, performance or achievements could be significantly different from those expressed information available to it as at the date of this presentation. This presentation contains general
Slide 3: Vision
Vision Our vision is to enable earlier and more accurate detection of cancer and other diseases to improve treatment options, patient outcomes and survival 3 | 9 AUGUST 2022
Slide 4: Company overview
Company overview INOVIQ Ltd Financial information (ASX:IIQ) • Developing diagnostic and exosome-based solutions for cancer Ordinary shares 92,018,702 and other diseases Share price (5/8/22) A$0.63 Market capitalisation A$57.97m • Proprietary technology platforms for biomarker isolation and detection
Slide 5: Unmet need for earlier cancer detection
Unmet need for earlier cancer detection Problem 5-year survival rates by stage at diagnosis1 ▪ Cancers are often diagnosed at late-stage after symptoms 120% have appeared, resulting in poor prognosis 100% 96% 99% 98%100% 90% 93% ▪ Detection of early-stage cancers often limited by high false- 77% 80%
Slide 6: Global cancer diagnostics market
Global cancer diagnostics market Global cancer burden is 50.6m 4.9m prevalence prevalence 7.8m survivors, 19.3m new cases and 10.0m 1.1m incidence $3.3b $4.2b incidence 2.3m deaths pa1 PROSTATE CANCER BREAST CANCER 375k deaths deaths 689k Global cancer diagnostics market valued at US$250b2 380k prev
Slide 7: Our technology platforms
Our technology platforms INOVIQ has patented technologies and products in-market SubB2M NETs BARD1 HTERT Highly specific probe that detects the NETs platform enables the capture of Biomarker technology covering various Anti-hTERT antibody technology that pan-cancer marker Neu5Gc found in target anal
Slide 8: Q4 FY22 quarterly highlights
Q4 FY22 quarterly highlights 8 | 9 AUGUST 2022
Slide 9: SubB2M | Improving the accuracy of existing standard of care tests
SubB2M | Improving the accuracy of existing standard of care tests • Master Manufacturing Agreement executed with cGMP and ISO-certified, MP Biomedicals for production of the SubB2M protein for SubB2M- based tests 2 • ResearchDx, a US-based contract diagnostics organisation, engaged to further devel
Slide 10: SubB2M | Papers and patents
SubB2M | Papers and patents • SubB2M paper published in high impact journal, BMC Cancer 1 Researchers conclude “Neu5Gc serum • SubB2M was used to show that Neu5Gc serum biomarkers are a promising new tool for biomarker levels can discriminate breast cancer disease monitoring for breast cancer that p
Slide 11: SubB2M | Melanoma IHC data
SubB2M | Melanoma IHC data • Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ’s SubB2M probe to aid in diagnosis of malignant melanoma in tissue samples 1 • Data from 144 tissue samples in this feasibility study demonstrated that SubB2M IHC detected melanoma with 91%
Slide 12: EXO-NET I Exosome isolation tools
EXO-NET I Exosome isolation tools • EXO-NET pan-exosome capture is a ‘research use only’ (RUO) product for isolation of exosomes from body fluids (plasma, urine and saliva) with speed, purity and yield advantages • Enables rapid, efficient and scalable isolation of enriched exosomes • Commercialisat
Slide 13: EXO-NET I Exosome-based diagnostics pipeline
EXO-NET I Exosome-based diagnostics pipeline Collaboration with UQ to develop world-first exosome-based ovarian cancer screening test1 AA OCRF-7 OCRF-7 BB CA-125 • UQ to develop exosome-based blood test for the 1.0 1.0 1.0 1.0 earlier detection of ovarian cancer under a $2.7m MRFF2 grant 0.8 0.8 0.8
Slide 14: EXO-NET I Commercial progress
EXO-NET I Commercial progress INOVIQ engages US-based contract sales team to accelerate EXO-NET roll out1 “We believe that EXO-NET is an important • INOVIQ engages US-based Percorso Life Sciences to provide contract sales force and logistics services to accelerate technology that will provide commer
Slide 15: EXO-NET | Papers and patents
EXO-NET | Papers and patents • Scientific Statement, co-authored by INOVIQ’s Chief Scientific Officer, Professor Greg Rice, published by the Endocrine Society 1 • The Statement outlines the emerging role of extracellular vesicles (EVs) in the field of endocrinology and the potential application of E
Slide 16: Strategy & Growth Plans
Strategy & Growth Plans 16 | 9 AUGUST 2022
Slide 17: Products and pipeline
Products and pipeline ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market Exosome-OC2 (OCRF-7) Ovarian Cancer Multiomic Screening (TBA) SubB
Slide 18: INOVIQ's scalable commercialisation strategy
INOVIQ’s scalable commercialisation strategy 2 Well trodden LDT to IVD commercialisation path Commercialise as EARLY REVENUES & INITIAL Lab Developed Tests Our strategy for commercialising MARKET ACCEPTANCE (LDT) diagnostics implements a risk-based LDT to IVD dual commercialisation path. We commerci
Slide 19: Achievements and catalysts
Achievements and catalysts 1Q 2022 2Q 2022 3Q 2022 4Q 2022 2023 ✓ EXO-NET collaborations ✓ SubB2M - New EXO-NET ✓ Secure LDT laboratory - SubB2M BC test results (UQ) assay development collaborations partner - SubB2M OC test results ✓ SubB2M manufacturing (ResearchDx) - EXO-NET publication ✓ Appoint
Slide 20: Investment proposition
Investment proposition Innovative Patented Strong Compelling Company Technology Pipeline Results Focused on diagnostic and Proprietary biomarker Multi-product pipeline Early data for SubB2M and 1 2 3 4 exosome-based solutions to isolation & detection for detection of common exosome-based tests show
Slide 21: Contacts
Contacts INOVIQ Ltd Dr Leearne Hinch Chief Executive Officer 23 Normanby Road Notting Hill VIC 3168 e. lhinch@inoviq.com Australia m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 21 | 9 AUGUST 2022
Slide 22: Appendices
Appendices 22 | 9 AUGUST 2022
Slide 23: Healthcare Experienced Board
Healthcare Experienced Board DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and international business Healthc
Slide 24: Management
Management DR LEEARNE HINCH DR GREG RICE PhD TONY DI PIETRO Dr ROCCO IANNELLO Chief Executive Officer Chief Scientific Officer CFO & Company Secretary Business Development and Licensing Director An experienced biotechnology executive and life An internationally recognised scientist with over 30 Exte
Slide 25: Strong patent portfolio
Strong patent portfolio Patent Family Title Granted Pending Expiry • Broad patent portfolio SubB2M protecting IIQ’s core BR, CA, CN, PCT/AU2017/051230 (WO 2018/085888) Subtilase cytotoxin B subunit mutant AU, US EP, IN, JP, 2037 biomarker isolation and KR, US (cont) detection technologies PCT/AU2022